Posted by Michael Wonder on 27 Apr 2022
Tucatinib for adults with HER2 positive advanced breast cancer
27 April 2022 - NICE has published evidence-based recommendations on the use of tucatinib for the treatment of adults with HER2 positive locally advanced or metastatic breast cancer.
Tucatinib, when used in combination with trastuzumab and capecitabine, is recommended as an option for the treatment of adults with HER2 positive locally advanced or metastatic breast cancer after two or more anti‑HER2 treatment therapies, only if Seagen provides tucatinib according to the commercial arrangement.
